CN105593363A - 含纳米气泡的组合物及其用途 - Google Patents
含纳米气泡的组合物及其用途 Download PDFInfo
- Publication number
- CN105593363A CN105593363A CN201580001311.2A CN201580001311A CN105593363A CN 105593363 A CN105593363 A CN 105593363A CN 201580001311 A CN201580001311 A CN 201580001311A CN 105593363 A CN105593363 A CN 105593363A
- Authority
- CN
- China
- Prior art keywords
- cell
- composition
- water
- agent
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 239000002101 nanobubble Substances 0.000 title claims abstract description 43
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000004321 preservation Methods 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000010261 cell growth Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 65
- 210000003470 mitochondria Anatomy 0.000 claims description 21
- 235000005911 diet Nutrition 0.000 claims description 13
- 230000037213 diet Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- 239000007952 growth promoter Substances 0.000 claims description 8
- 230000002438 mitochondrial effect Effects 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 10
- 235000013361 beverage Nutrition 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 238000005138 cryopreservation Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 36
- 239000001963 growth medium Substances 0.000 description 35
- 239000007789 gas Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 230000035622 drinking Effects 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 229930182536 Antimycin Natural products 0.000 description 9
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 9
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 8
- 235000020188 drinking water Nutrition 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 210000003423 ankle Anatomy 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 235000021185 dessert Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- DEAFEFSHUVGNFC-JTQLQIEISA-N (2s)-6-amino-2-(hexanoylamino)hexanoic acid Chemical compound CCCCCC(=O)N[C@H](C(O)=O)CCCCN DEAFEFSHUVGNFC-JTQLQIEISA-N 0.000 description 1
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
- JDSRHVWSAMTSSN-BSZOFBHHSA-N 13-HPODE Chemical compound CCCCCC(OO)\C=C\C=C/CCCCCCCC(O)=O JDSRHVWSAMTSSN-BSZOFBHHSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000008744 Brassica perviridis Nutrition 0.000 description 1
- 241000712024 Brassica rapa var. perviridis Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 101150002402 Smcp gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000015228 chicken nuggets Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003764 chromatophore Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000001551 hemic and immune system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000014612 sandwich biscuits Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
- A23P30/40—Foaming or whipping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Hydroponics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013273610 | 2013-12-27 | ||
| JP2013-273610 | 2013-12-27 | ||
| JP2014212676 | 2014-10-17 | ||
| JP2014-212676 | 2014-10-17 | ||
| PCT/JP2015/050073 WO2015099201A1 (fr) | 2013-12-27 | 2015-01-05 | Composition contenant des nanobulles, et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105593363A true CN105593363A (zh) | 2016-05-18 |
Family
ID=53479037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580001311.2A Pending CN105593363A (zh) | 2013-12-27 | 2015-01-05 | 含纳米气泡的组合物及其用途 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2016063804A (fr) |
| CN (1) | CN105593363A (fr) |
| HK (1) | HK1223975A1 (fr) |
| WO (1) | WO2015099201A1 (fr) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109415686A (zh) * | 2016-05-13 | 2019-03-01 | 希玛科技有限公司 | 可给药到活体的水溶液及其制备方法 |
| CN110227363A (zh) * | 2018-03-06 | 2019-09-13 | 四季洋圃生物机电股份有限公司 | 多功能超微气泡水实施方法及其制造装置 |
| CN111919990A (zh) * | 2020-08-04 | 2020-11-13 | 上海华鹿环保技术中心 | 一种纯天然纳米气泡保鲜水及其制备方法 |
| CN112203510A (zh) * | 2018-05-31 | 2021-01-08 | 学校法人爱知医科大学 | 生物材料保存组合物、生物材料的保存方法、生物材料的生产方法、移植材料和移植方法 |
| CN112218940A (zh) * | 2018-05-31 | 2021-01-12 | 学校法人爱知医科大学 | 组合物、细胞保存组合物、细胞培养组合物、细胞制剂、包含微小气泡的对象物的制造方法、细胞的保存方法、细胞的培养方法和细胞制剂的制造方法 |
| CN112236039A (zh) * | 2018-05-30 | 2021-01-15 | 株式会社水改质 | 白粉病的防治方法 |
| CN113209847A (zh) * | 2021-06-11 | 2021-08-06 | 同济大学 | 无菌纳米气泡水及其制备方法和应用 |
| CN114269385A (zh) * | 2019-06-26 | 2022-04-01 | 武田药品工业株式会社 | 转染方法 |
| CN114469758A (zh) * | 2022-01-25 | 2022-05-13 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
| WO2023197518A1 (fr) * | 2022-04-13 | 2023-10-19 | 西安北光医学生物技术有限公司 | Procédé de conservation contre les lésions et système de conservation pour des cellules, des tissus ou des organes |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017126647A1 (fr) * | 2016-01-21 | 2017-07-27 | 国立大学法人大阪大学 | Procédé de culture de cellules |
| WO2017154855A1 (fr) * | 2016-03-06 | 2017-09-14 | アクア・ゼスト株式会社 | Composition favorisant la régénération osseuse et appareil favorisant la régénération osseuse |
| JP6129395B1 (ja) * | 2016-10-29 | 2017-05-17 | 誠一 荒木 | ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤 |
| JP7149053B2 (ja) * | 2017-04-25 | 2022-10-06 | 株式会社田中金属製作所 | 糖尿病予防又は改善用液状物 |
| JP7041895B2 (ja) * | 2018-10-02 | 2022-03-25 | 株式会社ファーベスト | ミトコンドリア活性化材料、ミトコンドリア活性化組成物およびミトコンドリア活性化方法 |
| JP6890353B2 (ja) * | 2019-03-26 | 2021-06-18 | ＭｉＺ株式会社 | 分子状水素を含む腎臓疾患の腎機能改善のための組成物 |
| WO2021064995A1 (fr) * | 2019-10-04 | 2021-04-08 | フレンド株式会社 | Procédé d'évaluation et système d'évaluation pour l'efficacité d'un gaz mélangé à l'hydrogène sur un organisme vivant |
| WO2021070908A1 (fr) * | 2019-10-08 | 2021-04-15 | 岩谷産業株式会社 | Composition pour congéler des cellules, procédé de congélation de cellules, procédé de mise en culture de cellules et kit de congélation de cellules |
| JP6760630B1 (ja) * | 2019-10-29 | 2020-09-23 | 学校法人 愛知医科大学 | 微小気泡含有電解質液の製造方法および微小気泡含有電解質液の調製に用いる微小気泡含有溶媒の製造方法 |
| JP6828918B1 (ja) * | 2019-10-30 | 2021-02-10 | 浩平 池田 | 心停止後の自己心拍再開後の生存率改善剤 |
| JPWO2022019152A1 (fr) * | 2020-07-20 | 2022-01-27 | ||
| CN111972399B (zh) * | 2020-08-06 | 2021-11-30 | 温州医科大学 | 维持肝细胞活性的保存液 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009195889A (ja) * | 2008-02-25 | 2009-09-03 | Opt Creation:Kk | ナノバブル液体製造装置及びナノバブル液体 |
| WO2011139478A2 (fr) * | 2010-04-30 | 2011-11-10 | H R D Corporation | Application à cisaillement élevé utilisée dans une thérapie médicale |
| CN102413817A (zh) * | 2009-04-27 | 2012-04-11 | 利发利希奥公司 | 治疗胰岛素抗性和糖尿病的组合物和方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5120998B2 (ja) * | 2006-09-06 | 2013-01-16 | 国立大学法人 東京医科歯科大学 | 組織、細胞又は臓器の保存液 |
| JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
| JP2009082903A (ja) * | 2007-09-16 | 2009-04-23 | Sgk Kk | マイクロバブル生成装置。 |
| JP4921332B2 (ja) * | 2007-11-29 | 2012-04-25 | 株式会社Ｒｅｏ研究所 | 窒素ナノバブル水の製造方法 |
| JP4594996B2 (ja) * | 2008-05-02 | 2010-12-08 | 株式会社 シンワ | 微細気泡混合次亜塩素酸ナトリウム希釈液を用いた食品殺菌方法及び装置 |
| JP5773473B2 (ja) * | 2008-09-01 | 2015-09-02 | 田中 裕之 | Ｎｋ活性増強剤およびその利用 |
| JP2011078371A (ja) * | 2009-10-09 | 2011-04-21 | Tomotaka Marui | 細胞変化を促進する微小気泡含有組成物、およびその微小気泡含有組成物を製造する装置、ならびに微小気泡含有組成物を用いた細胞変化促進方法。 |
| JP5319607B2 (ja) * | 2010-05-31 | 2013-10-16 | 丸井 智敬 | 微小気泡を含有する液体の組成物、および、微小気泡を含有する組成物の製造方法 |
-
2015
- 2015-01-05 JP JP2015000580A patent/JP2016063804A/ja active Pending
- 2015-01-05 WO PCT/JP2015/050073 patent/WO2015099201A1/fr active Application Filing
- 2015-01-05 CN CN201580001311.2A patent/CN105593363A/zh active Pending
-
2016
- 2016-10-26 HK HK16112319.1A patent/HK1223975A1/zh unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009195889A (ja) * | 2008-02-25 | 2009-09-03 | Opt Creation:Kk | ナノバブル液体製造装置及びナノバブル液体 |
| CN102413817A (zh) * | 2009-04-27 | 2012-04-11 | 利发利希奥公司 | 治疗胰岛素抗性和糖尿病的组合物和方法 |
| WO2011139478A2 (fr) * | 2010-04-30 | 2011-11-10 | H R D Corporation | Application à cisaillement élevé utilisée dans une thérapie médicale |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109415686A (zh) * | 2016-05-13 | 2019-03-01 | 希玛科技有限公司 | 可给药到活体的水溶液及其制备方法 |
| CN110227363A (zh) * | 2018-03-06 | 2019-09-13 | 四季洋圃生物机电股份有限公司 | 多功能超微气泡水实施方法及其制造装置 |
| CN112236039A (zh) * | 2018-05-30 | 2021-01-15 | 株式会社水改质 | 白粉病的防治方法 |
| CN112203510A (zh) * | 2018-05-31 | 2021-01-08 | 学校法人爱知医科大学 | 生物材料保存组合物、生物材料的保存方法、生物材料的生产方法、移植材料和移植方法 |
| CN112218940A (zh) * | 2018-05-31 | 2021-01-12 | 学校法人爱知医科大学 | 组合物、细胞保存组合物、细胞培养组合物、细胞制剂、包含微小气泡的对象物的制造方法、细胞的保存方法、细胞的培养方法和细胞制剂的制造方法 |
| CN114269385A (zh) * | 2019-06-26 | 2022-04-01 | 武田药品工业株式会社 | 转染方法 |
| CN111919990A (zh) * | 2020-08-04 | 2020-11-13 | 上海华鹿环保技术中心 | 一种纯天然纳米气泡保鲜水及其制备方法 |
| CN113209847A (zh) * | 2021-06-11 | 2021-08-06 | 同济大学 | 无菌纳米气泡水及其制备方法和应用 |
| CN114469758A (zh) * | 2022-01-25 | 2022-05-13 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
| CN114469758B (zh) * | 2022-01-25 | 2024-02-20 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
| WO2023197518A1 (fr) * | 2022-04-13 | 2023-10-19 | 西安北光医学生物技术有限公司 | Procédé de conservation contre les lésions et système de conservation pour des cellules, des tissus ou des organes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015099201A1 (fr) | 2015-07-02 |
| JP2016063804A (ja) | 2016-04-28 |
| HK1223975A1 (zh) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105593363A (zh) | 含纳米气泡的组合物及其用途 | |
| US20190046563A1 (en) | Nanobubble-containing composition and use thereof | |
| CN110730615A (zh) | 含培养肉的混合食品 | |
| CN102028034B (zh) | 一种酸性抗氧化液态乳制品及其制备方法 | |
| CN104489096B (zh) | 一种高蛋白无乳糖牛奶及其制备方法 | |
| US20210329957A1 (en) | Beet juice with increased intestinal absorption, its manufacturing method and its use | |
| CN105395565A (zh) | 人参皂苷f2的肝病预防或治疗用途 | |
| Barua et al. | Underutilized fruits of Assam for livelihood and nutritional security | |
| WALKER et al. | Estrogenic substances. II. An analysis of plant sources | |
| CN113631175A (zh) | 以阿洛糖醇为有效成分的抗肥胖活性剂和肥胖抑制方法 | |
| TW202302134A (zh) | 諾麗果發酵物於製備改善體態及肌膚狀況之組合物之用途 | |
| KR102028634B1 (ko) | 토사자 추출물을 또는 그의 분획물을 포함하는 갱년기성 심혈관계 질환의 예방 및 치료용 조성물 | |
| KR100699782B1 (ko) | 댕댕이나무 추출물을 포함하는 간 기능 회복용 식품 조성물 | |
| KR20160059137A (ko) | 유산균 및 천연효소를 이용한 발효삼채 제조 및 숙취해소용 혼합음료 제조방법 | |
| Fediuk | Vitamin C in the Inuit diet: past and present | |
| JP6366279B2 (ja) | 過活動膀胱の予防又は改善剤 | |
| Ogunmefun et al. | Nutritional values, chemical compositions and antimicrobial activities of fruit juice from pineapple (Ananas comosus L.) and coconut (Cocos nucifera L.) blends | |
| JP2018150240A (ja) | 骨形成促進剤及びそれを用いた飲食品組成物 | |
| CN106754427A (zh) | 嗜蓝孢孔菌新菌株及其驯化方法 | |
| STEARNS et al. | Excretion of thiamine and riboflavin by children | |
| KR20160143938A (ko) | 개똥쑥 열수추출물의 제조방법 및 이를 함유하는 식품조성물 | |
| Mohammed et al. | Comparative study among watermelon crud extract, citrulline and lycopene on some reproductive indices in male mice | |
| CN100393242C (zh) | 一种延年益寿的保健制剂及其制备方法 | |
| Smith | Practical Dietary for Families, Schools, and the Labouring Classes | |
| TW200417366A (en) | Remedy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1223975 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160518 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1223975 Country of ref document: HK |